| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,825,567 |
| 52
Week Range: |
$0.5775 - $0.5775 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yarno Wendy L |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
10,512 |
|
- |
|
| Shepard Jay |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
9,209 |
|
- |
|
| Dansey Roger D |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
8,916 |
|
- |
|
| Miller Ann Calby |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
9,877 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
12,191 |
|
- |
|
| Zoth Lota S |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
8,726 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2025-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,167 |
86,620 |
|
- |
|
| Sumner Michael John |
Chief Medical Officer |
• – – |
2025-05-15 |
4 |
D |
$1.95 |
$1,326 |
D/D |
(680) |
14,934 |
|
- |
|
| Sumner Michael John |
Chief Medical Officer |
• – – |
2025-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,385 |
15,614 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2025-05-15 |
4 |
D |
$1.95 |
$5,004 |
D/D |
(2,566) |
30,257 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2025-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,771 |
32,823 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2025-05-15 |
4 |
D |
$1.95 |
$3,331 |
D/D |
(1,708) |
32,622 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2025-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,771 |
34,330 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2025-05-15 |
4 |
D |
$1.95 |
$15,048 |
D/D |
(7,717) |
59,685 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2025-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,744 |
67,402 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2025-05-10 |
4 |
D |
$1.80 |
$4,306 |
D/D |
(2,392) |
49,658 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2025-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
52,050 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,944 |
84,453 |
|
- |
|
| Sumner Michael John |
Chief Medical Officer |
• – – |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,010 |
13,229 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2025-02-26 |
4 |
D |
$1.98 |
$22,930 |
D/D |
(11,581) |
46,550 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Executive Officer |
• • – |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,484 |
55,638 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2025-02-26 |
4 |
D |
$1.98 |
$10,538 |
D/D |
(5,322) |
28,052 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,007 |
31,012 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2025-02-26 |
4 |
D |
$1.98 |
$7,213 |
D/D |
(3,643) |
29,559 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2025-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,865 |
31,618 |
|
- |
|
399 Records found
|
|
Page 1 of 16 |
|
|
